MBA 699 Module 5 Milestone Three Buyer Research and Road Map example

Milestone Three: Alternative Buyer Research and Acquisition Road Map for Prairieview Life Sciences

[Student Name]

Southern New Hampshire University

MBA 699: Strategic Opportunity Management

Module Five Milestone Three

[Instructor Name]

[Date]

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

Milestone Three: Alternative Buyer Research and Acquisition Road Map for Prairieview Life Sciences

Purpose and Criteria

The industry analysis concluded that Prairieview's hardest-to-copy resources are its seven approved commercial processes, its FDA inspection record and its experienced process development team, and the attrition analysis showed that manufacturing turnover is the main risk a buyer will price in. This milestone researches three buyer types identified in that analysis and recommends which to prioritize. Buyers are scored from 1 to 5 on five weighted criteria: strategic fit with Prairieview's capabilities (30 percent), the value the buyer would place on its distinctive resources (20 percent), likely price and terms (20 percent), expected treatment of the workforce (15 percent) and the risk that the buyer's ownership would drive away existing clients (15 percent).

Buyer A: Global Contract Manufacturer

Buyer A, called Harborline Biologics here, is a composite global contract manufacturer with large plants in Europe and Asia and only one small U.S. site. Its clients increasingly ask for U.S.-based supply, and building a new plant would take several years. Prairieview would give it immediate domestic capacity, approved commercial processes and a team able to run them. Harborline's own business depends on serving many pharmaceutical clients without competing with them, so Prairieview's existing clients would face little conflict. Its record in earlier acquisitions has been to keep acquired plants running under local management, though it has standardized quality systems quickly.

Buyer B: Biotechnology Company

Buyer B, called Carrow Therapeutics, is a composite mid-size biotechnology company with two approved antibody drugs and four more in late trials. It currently depends on outside manufacturers and wants control of its supply. It would likely pay the highest price, since owning capacity would secure its pipeline. However, Carrow would gradually fill Prairieview's plants with its own products, and several existing clients, some of whom compete with Carrow in the same disease areas, have indicated that they would move their products if a competitor owned their manufacturer.

Buyer C: Private Equity Firm

Buyer C, called Ridgeway Capital Partners, is a composite private equity firm assembling a group of mid-size contract manufacturers. It would keep Prairieview independent in name and management and add capital for expansion, but it would finance the purchase partly with debt and expect margin improvement before a resale in four to six years. It offers the least disruption to clients and employees in the near term and the lowest likely price.

Scoring the Buyers

Table 1 applies the weighted criteria.

Table 1

Weighted Scoring of Alternative Buyers

Note. Composite scores assigned by the guiding coalition.

Beyond the Scores: How Each Buyer Would Integrate

Haspeslagh and Jemison (1991) distinguished acquisitions by how much the buyer needs to integrate the target to create value and how much the target's autonomy must be preserved to keep that value. Harborline would most likely pursue a symbiotic approach, linking Prairieview to its network and quality systems while leaving plant operations with local leaders. Carrow would absorb Prairieview into its own supply operation over time. Ridgeway would preserve Prairieview largely as it is. Ranft and Lord (2002) found that in acquisitions made for capabilities, rapid integration risks losing the people who hold the knowledge being bought, which makes Carrow's absorption the riskiest path for Prairieview's scientists and technicians despite its high price.

Culture also matters. Cartwright and Cooper (1993) argued that compatibility of cultures is a major factor in whether combinations succeed. Harborline's operations-focused, quality-driven culture resembles Prairieview's more closely than Carrow's research culture or Ridgeway's financial focus. The buyer that pays the most is not the buyer most likely to keep what makes Prairieview worth buying.

Recommendation

The coalition should approach Harborline as the preferred buyer and Carrow as a competitive alternative, and should keep Ridgeway as a fallback if strategic buyers' offers fall short. Running a limited process with several interested parties protects price, while the preference for Harborline protects the clients and workforce. Retention agreements for the 50 critical employees and the manufacturing stabilization plan must be in place before the first buyer meeting.

Acquisition Road Map

Table 2 presents the road map as seven phases over 44 weeks.

Table 2

Acquisition Road Map by Phase

Note. Composite timeline. Weeks count from the board's approval to proceed.

Critical Points in the Timeline

Three points deserve particular attention. The moment of greatest leak risk is the start of management meetings in phase four, when buyers visit the plants; site visits will be scheduled on weekends and described internally as client audits where possible. The employee announcement in phase six should come immediately after signing, with the buyer's commitments on jobs and roles, since uncertainty is when departures accelerate. Client consents are also a risk: several contracts require client approval of a change of control, and the general counsel should identify these during preparation rather than after signing. If any phase slips, the coalition should protect the retention and communication steps rather than compress them to save time.

References

Cartwright, S., & Cooper, C. L. (1993). The role of culture compatibility in successful organizational marriage. Academy of Management Executive, 7(2), 57-70. https://doi.org/10.5465/ame.1993.9411302324

Haspeslagh, P. C., & Jemison, D. B. (1991). Managing acquisitions: Creating value through corporate renewal. Free Press.

Ranft, A. L., & Lord, M. D. (2002). Acquiring new technologies and capabilities: A grounded model of acquisition implementation. Organization Science, 13(4), 420-441. https://doi.org/10.1287/orsc.13.4.420.2952